Cutting edge: Recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection

Journal of Immunology

Volumn 178, Issue 8, 2007, Pages 4731-4735

  Orr, Mark T ^a   Orgun, Nural N ^a   Wilson, Christopher B ^a   Way, Sing Sing ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HERPES SIMPLEX VACCINE; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; IMMUNIZATION; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; VIRUS IMMUNITY; VIRUS RESISTANCE;

EID: 34247110955     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.8.4731     Document Type: Article

References (31)

1. Smith, J. S., and N. J. Robinson. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and I: a global review. J. Infect. Dis. 186(Suppl. 1): S3-S28.
2. Kimberlin, D. 2004. Herpes simplex virus, meningitis and encephalitis in neonates. Herpes 11(Suppl. 2): 65A-76A.
3. Kimberlin, D. W., C. Y. Lin, R. F. Jacobs, D. A. Powell, L. Corey, W. C. Gruber, M. Rathore, J. S. Bradley, P. S. Diaz, M. Kumar, et al. 2001. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108: 230-238.
4. Danve-Szatanek, C., M. Aymard, D. Thouvenot, F. Morfin, G. Agius, I. Bertin, S. Billaudel, B. Chanzy, M. Coste-Burel, L. Finkielsztejn, et al. 2004. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J. Clin. Microbiol. 42: 242-249.
5. Stranska, R., R. Schuurman, E. Nienhuis, I. W. Goedegebuure, M. Polman, J. F. Weel, P. M. Werrheim-Van Dillen, R. J. Berkhout, and A. M. van Loon. 2005. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterizarion. J. Clin. Virol. 32: 7-18.
6. Koelle, D. M., C. M. Posavad, G. R. Barnum, M. L. Johnson, J. M. Frank, and L. Corey. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Invest. 101:1500-1508.
7. + T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation. J. Immunol. 172: 392-397.
8. Simmons, A., and D. C. Tscharke. 1992. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J. Exp. Med. 175: 1337-1344.
9. + T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J. Exp. Med. 175: 1531-1538.
10. Harry, J. T., and E. G. Pamer. 1995. CD8 T lymphocytes specific for the secreted p60 antigen protect against Listeria monocytogenes infection. J. Immunol. 154: 4642-4650.
11. Frankel, F. R., S. Hegde, J. Lieberman, and Y. Paterson. 1995. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J. Immunol. 155: 4775-4782.
12. Zhao, X., M. Zhang, Z. Li, and F. R. Frankel. 2006. Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag. J. Virol. 80: 8880-8890.
13. Rayevskaya, M. V., and F. R. Frankel. 2001. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J. Virol. 75: 2786-2791.
14. Shen, H., M. K. Slifka, M. Matloubian, E. R. Jensen, R. Ahmed, and J. F. Miller. 1995. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc. Natl. Acad. Sci. USA 92: 3987-3991.
15. Boyer, J. D., T. M. Robinson, P. C. Maciag, X. Peng, R. S. Johnson, G. Pavlakis, M. G. Lewis, A. Shen, R. Siliciano, C. R. Brown, et al. 2005. DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology 333: 88-101.
16. Stevens, R., K. E. Howard, S. Nordone, M. Burkhard, and G. A. Dean. 2004. Oral immunization with recombinant Listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus. J. Virol. 78: 8210-8218.
17. Ikonomidis, G., D. A. Portnoy, W. Gerhard, and Y. Paterson. 1997. Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines. Vaccine 15: 433-440.
18. Brundage, R. A., G. A. Smith, A. Camilli, J. A. Theriot, and D. A. Portnoy. 1993. Expression and phosphorylation of the Listeria monocytogenes ActA protein in mammalian cells. Proc. Natl. Acad. Sci. USA 90: 11890-11894.
19. Foulds, K. E., L. A. Zenewicz, D. J. Shedlock, J. Jiang, A. E. Troy, and H. Shen. 2002. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol 168: 1528-1532.
20. Park, S. F., and G. S. Stewart. 1990. High-efficiency transformation of Listeria monocytogenes by electroporation of penicillin-treated cells. Gene 94: 129-132.
21. Wirth, R., F. Y. An, and D. B. Clewell. 1986. Highly efficient protoplast transformation system for Streptococcus faecalis and a new Escherichia coli-S. faecalis shuttle vector. J Bacteriol. 165:831-836.
22. Orr, M. T., K. H. Edelmann, J. Vieira, L. Corey, D. H. Raulet, and C. B. Wilson. 2005. Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice. PLoS Pathog. 1: e7.
23. Way, S. S., T. R. Kollmann, A. M. Hajjar, and C. B. Wilson. 2003. Cutting edge: protective cell-mediated immunity to Listeria monocytogenes in the absence of myeloid differentiation factor 88. J. Immunol. 171: 533-537.
24. Harry, J. T., and M. J. Bevan. 1995. Specific immunity to Listeria monocytogenes in the absence of IFNγ. Immunity 3: 109-117.
25. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342.
26. Stevens, R., A. Lavoy, S. Nordone, M. Burkhard, and G. A. Dean. 2005. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine. Vaccine 23: 1479-1490.
27. Starks, H., K. W. Bruhn, H. Shen, R. A. Barry, T. W. Dubensky, D. Brockstedt, D. J. Hinrichs, D. E. Higgins, J. F. Miller, M. Giedlin, and H. G. Bouwer. 2004. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J. Immunol. 173: 420-427.
28. Brockstedt, D. G., M. A. Giedlin, M. L. Leong, K. S. Bahjat, Y. Gao, W. Luckett, W. Liu, D. N. Cook, D. A. Portnoy, and T. W. Dubensky, Jr. 2004. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. USA 101: 13832-13837.
29. Lieberman, J., and F. R. Frankel. 2002. Engineered Listeria monocytogenes as an AIDS vaccine. Vaccine 20: 2007-2010.
30. Koelle, D. M. 2006. Vaccines for herpes simplex virus infections. Curr. Opin. Investig. Drugs 7: 136-141.
31. Stanberry, L. R. 2004. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11: 161A-169A.